Dietil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dietil

Quick Facts

Property Description
Active ingredient Orlistat
Form Hard Capsule
Pharmacological class Lipase Inhibitor, Anti-obesity Agent
General purpose Weight management, reducing fat absorption
Origin Synthetic, derived from Lipstatin

What Type of Medicine is Dietil (Orlistat)?

Dietil is a pharmaceutical product, whose active ingredient is Orlistat (INN), used as an Anti-obesity Agent in weight management. Orlistat belongs to the distinct pharmacological class of Lipase Inhibitors, a classification based on its specific, localized mechanism of action. This medicine is a synthetic small molecule, though its structure is a derivative of Lipstatin, a compound originally sourced from the bacterium Streptomyces toxytricini. Dietil is a specific hard capsule formulation of Orlistat, confirming its identity as a distinct brand containing the single active agent.

Composition and Form: The Delivery of Orlistat

The medicine is supplied for oral administration primarily in the form of a hard capsule. This oral dosage form ensures targeted delivery to the gastrointestinal tract, as Orlistat is designed to work locally by inhibiting lipase enzymes, with minimal systemic absorption into the bloodstream. The composition includes the active ingredient, Orlistat, and necessary pharmaceutical excipients within the capsule.

General Purpose and Mechanism of Benefit

The general purpose of Dietil is to support weight loss and weight maintenance by decreasing the absorption of dietary fat calories. This benefit is achieved because Orlistat works by binding to and inactivating the key enzymes (gastric and pancreatic lipases) responsible for breaking down fat in the gut. This non-systemic action is fundamental to its role, leading to a required caloric deficit to aid in managing obesity through a localized mechanism.

Regulatory References

  1. Xenical (Orlistat) European Public Assessment Report (EPAR)

What side effects are possible with Dietil?

Possible Side Effects and Safety Information

The safety profile of Dietil (Orlistat) is prominently characterized by effects related to its localized action within the gastrointestinal tract. Regulatory documents classify certain Gastrointestinal Disorders as Very Common, meaning they occur in more than 1 in 10 individuals. These effects often include the presence of oily spotting or discharge, fecal urgency, flatus with discharge, and fatty or oily stool.


Organ-System Safety Concerns

Side effects are officially documented across several System-Organ Classes. While the GI system is primary, postmarketing surveillance has led to official warnings regarding Hepatobiliary Disorders and Renal and Urinary Disorders. Reports of Severe Liver Injury, including acute hepatic failure, and cases of Acute Oxalate Nephropathy are included in regulatory documentation as serious adverse reactions.

Common non-gastrointestinal adverse events reported include headache and symptoms related to upper respiratory tract infection.


Contextual Safety Patterns

The incidence of the common gastrointestinal effects is documented to be substantially higher during the first year of treatment and is officially noted to increase with the consumption of a high-fat diet. Furthermore, regulatory labeling identifies specific safety limitations: the medicine is contraindicated in patients with conditions such as Chronic Malabsorption Syndrome or Cholestasis. For special populations, it is listed as contraindicated during pregnancy, while the safety profile in adolescents (12–16 years) is generally considered similar to that of adults.

Overdose and Emergency Response

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Acute single doses of up to 800 mg or multiple doses up to 400 mg three times daily for 15 days in clinical trials did not result in clinically significant adverse findings. Symptoms, if they occur, are generally similar to those observed at the recommended therapeutic dose.
Physiological systems affected Any potential systemic effects are expected to be rapidly reversible upon drug cessation due to its minimal absorption. Urgent evaluation is necessary for signs of severe liver injury (jaundice, dark urine) or kidney problems (e.g., severe back pain, blood in urine) which are critical help-seeking triggers.
Population-specific overdose notes The effects in patients with hepatic impairment, renal impairment, children, and the elderly have not been specifically studied or documented in regulatory labeling.
Emergency-response statements The patient should be observed for at least 24 hours following a significant overdose. Management of over-exposure is defined as symptomatic and supportive treatment.
When immediate medical help is required Contact emergency services (911/equivalent) immediately if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications

Classification Official Regulatory Statement
Severity classification Acute overdose exposure, up to the tested doses, is classified as having no clinically significant adverse findings documented by regulators.
Antidote information No specific antidote for Orlistat overdose is currently documented in the official prescribing information.

Connection to the overall overdose profile: Regulatory documents establish that acute Orlistat overdose is not associated with unique severe systemic toxicity, which drives the primary management protocol of observation and supportive care. The specific mandate for 24-hour observation communicates the monitoring requirement established by regulatory authorities. Immediate contact with emergency services is required when general, life-threatening symptoms, such as collapse or respiratory distress, are present, requiring urgent stabilization.

Therapeutic Uses of Dietil

The therapeutic use of medications in this category is generally relevant for managing symptoms associated with allergic rhinitis, especially when nasal congestion is a factor. Treatments in this class are applicable across domains where additional symptomatic support is needed. Dietil is generally relevant in conditions characterized by periods of heightened symptoms, such as seasonal or perennial allergy manifestations.


Relief and Support During Symptom Episodes

Dietil is commonly used to help with symptoms related to physical discomfort associated with upper respiratory symptoms. It is applied in addressing symptom clusters that may become intense or disruptive, such as nasal congestion, runny nose, excessive sneezing, and itchy, watery eyes. The medication may assist with managing these symptom clusters and contributes to improved day-to-day comfort during symptomatic periods.

“The medication is commonly used when short-term symptomatic assistance is needed.”

It is commonly used when supportive symptom management is appropriate during phases when symptoms become more noticeable, such as during seasonal flare-ups or when exposed to indoor allergens. It supports the patient during difficult episodes by helping to ease discomfort and **may assist with maintaining functional stability.


QuickFact Block

Feature Detail
Quick Fact Relief for Nasal Congestion and Runny Nose
Used For Conditions involving episodic or fluctuating manifestations
Benefit Supports general well-being during symptomatic phases

Eligibility and Restrictions for Use

Who can and cannot use Dietil?

Dietil (Orlistat) use is officially established for Adults who meet specific Body Mass Index (BMI) criteria. This includes those with a BMI of ge 30 kg/m^2 (obese), or those with a BMI of ge 27 kg/m^2 in the presence of associated health risks such as hypertension or diabetes. Use is also permitted for Adolescents aged 12 years and older for the prescription strength formulation.


The medicine is contraindicated and must not be used by several population groups, as stated in regulatory labeling:

  • Patients with Chronic Malabsorption Syndrome or Cholestasis (impaired bile flow).
  • Women who are pregnant or breastfeeding.
  • Patients with known hypersensitivity to Orlistat or any of its components.

Condition-Specific Restrictions

Certain patients require restricted or conditional use. For instance, those with pre-existing Chronic Kidney Disease (CKD) should be monitored due to the regulatory-documented risk of oxalate nephrolithiasis. Furthermore, the non-prescription formulation is generally not recommended for individuals under the age of 18 or for organ transplant recipients taking immunosuppressive drugs like Cyclosporine. Safety and efficacy are not established in children younger than 12 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dietil (Orlistat) interacts with specific substances primarily through a pharmacokinetic interaction mechanism involving the reduced absorption of lipophilic compounds in the gastrointestinal tract, a fact documented in regulatory labels.

Official Interaction Restrictions

Co-administration with Warfarin or other Oral Anticoagulants is formally contraindicated due to the risk of unstable coagulation parameters resulting from impaired Vitamin K absorption. The concurrent use of Cyclosporine is also restricted by some authorities, requiring strict adherence to timing rules or being formally prohibited to avoid critically low plasma levels.

Documented Exposure Modification

Interacting Substance Official Interaction Outcome
Levothyroxine Reduced absorption and potential decrease in plasma concentration.
Antiretroviral Products Potential reduction in absorption, linked to a risk of losing virological control.
Fat-soluble Vitamins (A, D, E, K) Impaired absorption, necessitating a mandatory timing separation of at least two hours from Dietil administration.

Co-administration with Antiepileptic Drugs carries a documented risk of reduced absorption and loss of seizure control. In patients with Type II Diabetes, official documents note that weight changes may require close monitoring and potential adjustment of antidiabetic medicines.

Mechanism of Action

Specific Enzyme Inactivation in the Gut

This mechanism centers on the peripheral inhibition of gastric and pancreatic lipases, the primary enzymes responsible for dietary fat breakdown. The active ingredient, Orlistat, forms a covalent bond with the active site of these lipases, leading to their irreversible inactivation . This specific action is non-systemic, ensuring that the drug's effect is confined entirely to the lumen of the stomach and small intestine.


Impairing Triglyceride Hydrolysis

The primary physiological consequence of enzyme inactivation is the direct impairment of triglyceride hydrolysis. Since the large dietary fat molecules cannot be broken down into absorbable free fatty acids and monoglycerides, up to 30% of ingested fat remains undigested. This undigested fat is subsequently excreted, resulting in a net exclusion of fat-derived calories, which contributes to a caloric deficit that affects the systemic energy balance.

Dosage and Administration Information

How to Use Dietil

The administration of Dietil (Orlistat) is designed around its localized action and is strictly dependent on concurrent dietary patterns. It is an oral medicine supplied in hard capsule form. The standard dose for prescription-strength use is one 120 mg capsule, taken three times daily (TID).


Administration Protocol

Dietil must be administered either immediately before, during, or up to one hour after each of the three main meals of the day that contain fat. This precise timing is a key procedural requirement. If a meal is missed entirely or contains no fat, the corresponding dose of Dietil should be omitted, emphasizing the direct link between use and dietary fat intake. Doses exceeding 120 mg TID are not associated with greater efficacy.

The medicine is intended for use in conjunction with a nutritionally balanced, mildly hypocaloric diet where approximately 30% of total calories are derived from fat. To ensure proper administration, any required multivitamin supplement should be taken at least two hours after the dose or at bedtime.


Use Duration and Specific Populations

Treatment must be discontinued if a patient has not achieved a weight loss of at least 5% of initial body weight after 12 consecutive weeks of therapy. For specific populations, the 120 mg TID regimen is approved for use in adolescents 12 years of age and older. No specific dose adjustments are typically required for older adults or those with renal or hepatic impairment due to the drug's minimal systemic absorption.

Recent Clinical Evidence

Dietil: Recent Clinical Evidence

The clinical evaluation of Dietil (Orlistat) was studied for use as an addition to a reduced-calorie, lower-fat diet, primarily focusing on individuals classified as overweight or obese. The foundation of this evidence is built upon numerous Randomized Controlled Trials (RCTs) and subsequent systematic reviews.

Evaluation of Weight Management and Outcomes

Research was studied for weight management by structuring short-term to intermediate-term RCTs, where participants received either the medicine or a placebo alongside dietary changes. Researchers examined measured changes in body weight, Body Mass Index (BMI), and waist circumference over defined periods. Studies monitored patterns that included differences in measured body weight between the groups, highlighting the need for concurrent dietary intervention. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

Research also was studied for metabolic outcomes, often as secondary objectives. These studies examined biomarkers in populations with conditions like Type 2 Diabetes or elevated cholesterol. Findings show patterns related to measured changes in markers such as LDL-C and HbA₁c, especially in patient subgroups where a shift in body weight was observed. Studies have also evaluated populations over periods up to four years to monitor weight maintenance, and have included specific patient populations such as adolescents aged 12 years and older.

Research Gaps and Limitations

While research has explored these outcomes, evidence is limited from large-scale, dedicated trials focusing on long-term cardiovascular outcomes. Existing research relies on surrogate markers (e.g., changes in cholesterol) to describe the evidence landscape. Additionally, generalizability is uncertain for sustained effects, as high patient dropout rates in extended-duration trials mean the data for long-term weight maintenance are still emerging. Data for certain groups remain insufficient, and certainty remains low regarding outcomes in some specialty populations.

Key Studies & References

  1. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial
  2. Efficacy of orlistat in type 2 diabetes: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Dietil (FAQ)

Q: How quickly should I expect Dietil to start working?

The official product information indicates that the medicine works locally in the digestive system by rapidly blocking the enzymes that break down fat. This action is consistent with a physiological effect that can begin after the first dose.


Q: Can Dietil be taken long-term?

Official guidelines require that treatment be discontinued if a patient has not achieved at least 5% weight loss after 12 consecutive weeks of use. However, clinical studies have examined the medicine’s use for periods up to four years for the purpose of monitoring weight maintenance.


Q: How long does the effect of one dose of Dietil usually last?

The active ingredient forms an irreversible bond with the fat-breaking enzymes, meaning the blockage is long-lasting. The duration of this inhibition in the body is determined by the rate at which your body naturally produces and replaces those digestive enzymes.


Q: Can Dietil cause weight changes?

According to the official product information, the primary purpose of this medicine is to support weight loss and the maintenance of a lower weight by reducing the absorption of calories from fat. Unintended weight gain is not listed in regulatory documents as an adverse event of the medicine itself.


Q: Is it common to feel tired while taking Dietil?

Regulatory documents include feeling tired or weak among the reported non-gastrointestinal side effects.


Q: What happens if I accidentally take too much Dietil?

Studies have examined high single doses and repeated doses larger than the standard amount with minimal adverse findings. Official guidance regarding taking more than the prescribed amount is available through a healthcare professional or poison control center.


Q: How often are the side effects of Dietil reported?

Official documents describe the frequency of side effects, such as gastrointestinal events, with terms like "Very Common," meaning they affect more than 1 in 10 individuals. The information notes that the incidence of common gastrointestinal side effects is documented to be substantially higher during the first year of treatment.


Q: Do studies support the long-term use of Dietil?

Clinical trials have included evaluation periods of up to four years to examine the maintenance of weight loss. Regulatory documents state that data for sustained weight maintenance and certain long-term outcomes are still being collected and analyzed.


Q: Does Dietil have any restrictions regarding food or drinks?

The medicine must be administered with meals that contain fat for it to work. Official warnings also state that the consumption of a high-fat diet increases the incidence of common gastrointestinal side effects. No general restrictions are listed for other non-alcoholic, non-fat-containing drinks.


Q: Are there any serious or rare side effects I should be aware of for Dietil?

Regulatory documents include warnings about rare, serious adverse reactions, such as Severe Liver Injury and Acute Oxalate Nephropathy (a kidney issue). Individuals should be aware of the symptoms of liver problems, which have been reported in very rare cases.


Q: Can Dietil affect my sleep?

Sleep disturbance is not listed as a common direct side effect. However, for certain patients taking anti-diabetic medicines, signs of low blood sugar (hypoglycemia) can occur, and regulatory information notes that these signs can include feeling sleepy.


Q: Can Dietil be used by children?

Official use conditions indicate that the prescription-strength formulation is approved for adolescents 12 years of age and older. Safety and efficacy are not established in children younger than 12 years.


Q: How is Dietil different from other medicines that treat the same condition?

Dietil is classified as a Lipase Inhibitor, which means it works only within the digestive system to block fat-breaking enzymes. This is a non-systemic mechanism of action that is distinct from other weight-management medicines that act on the brain or central nervous system.


Q: Does taking Dietil mean I have to stop drinking alcohol?

Official drug interaction information generally shows no direct interaction has been found between the active ingredient and alcohol.


Q: Are there any vitamins or supplements that interact with Dietil?

Official interaction documents specifically note that absorption of fat-soluble vitamins (A, D, E, K) may be reduced. There is no general regulatory guidance covering all possible herbal or mineral supplements.


Q: Does Dietil interact with blood pressure medication?

Studies have examined the potential interaction with antihypertensive agents (blood pressure drugs). Regulatory information notes that weight loss may be associated with potential adjustment of co-administered medicines, including those for blood pressure.


Q: Can Dietil be taken with over-the-counter pain relievers like ibuprofen?

Official interaction information generally shows no direct interaction has been found between the active ingredient and common over-the-counter pain relievers such as ibuprofen.


Q: What is the risk of Dietil causing dizziness?

Dizziness is not listed as a common direct side effect. However, it is a reported sign of low blood sugar (hypoglycemia), which is a potential risk for some patients, particularly those co-administering anti-diabetic medicines.


Q: Is there a generic version of Dietil available?

Official regulatory sources in Europe and the US have noted that generic versions of the active ingredient, Orlistat, have been authorized for use.


Q: Is Dietil used in other countries besides the US?

The medicine and its active ingredient are recognized and have been authorized for use in numerous countries outside of the US, including those under the jurisdiction of the European Medicines Agency (EMA).


Q: Does Dietil interact with birth control pills?

Specific drug-drug interaction studies have not demonstrated a direct interaction with oral contraceptives. However, official information notes that the medicine may indirectly reduce the availability of oral contraceptives if severe diarrhea occurs.


Q: Is it possible to develop a tolerance to Dietil over time?

Non-clinical evidence indicates that the magnitude of lipase inhibition, which is the mechanism of action, did not change during long-term administration. The medicine is not a centrally acting agent that causes pharmacological tolerance.


Q: Does Dietil cause stomach upset or nausea?

Regulatory documents list stomach pain and other abdominal symptoms as common side effects. Nausea is also reported, including as a symptom associated with rare, serious adverse events like liver injury.


Q: Is Dietil used for prevention or just for treatment of the condition?

The official purpose is to support both weight loss and the maintenance of a lower weight. The maintenance indication is considered supportive in preventing weight regain.


Q: Can men and women use Dietil in the same way?

The official regulatory documents provide the same dosing and administration instructions for both men and women who meet the Body Mass Index and age criteria. No sex-specific instructions are specified.


Q: Are there any warnings about driving or operating machinery while on Dietil?

Regulatory documents state that the medicine does not generally affect the ability to drive or operate machinery. However, if an individual experiences side effects such as dizziness or sleepiness, caution may be appropriate.

How should Dietil be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling for Orlistat hard capsules defines specific requirements for storage and handling to maintain product stability and safety.

Storage Conditions: The medicine must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). It is essential to protect the capsules from moisture and light and keep them away from excessive heat or cold; do not freeze the product. The medicine must remain in its original container and the bottle should be kept tightly closed.

Safety and Disposal: Consistent with labeling, the medicine must be kept out of the sight and reach of children. Unused or expired capsules should be disposed of via an authorized drug take-back program. Medicines must not be discarded into household trash or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dietil found in:

A-Z Index: